10:27 AM EST, 11/24/2025 (MT Newswires) -- NeuroSense Therapeutics ( NRSN ) said Monday it has been cleared by US Food and Drug Administration to begin a phase 3 trial for PrimeC to treat amyotrophic lateral sclerosis.

The company aims to enroll its first patient in the coming months. The trial is expected to be conducted in the US and EU and include 300 participants, the company said.

Shares of NeuroSense Therapeutics ( NRSN ) rose by more than 4% in recent trading.

Price: 1.15, Change: +0.05, Percent Change: +4.64